Factor XIII Val 34 Leu
- 1 April 1998
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 29 (4), 813-816
- https://doi.org/10.1161/01.str.29.4.813
Abstract
Background and Purpose —A common G-to-T point mutation (Val 34 Leu) in exon 2 of the α-subunit of the factor XIII is strongly negatively associated with the development of myocardial infarction. This result suggests that factor XIII Val 34 Leu is interfering with the formation of cross-linked fibrin. The role of factor XIII Val 34 Leu in the pathogenesis of cerebral infarction and primary intracerebral hemorrhage is unknown. Methods —Six hundred twelve patients with acute stroke, defined by World Health Organization criteria and cranial CT, and 436 age-matched control subjects free of cerebrovascular disease were genotyped for the factor XIII Val 34 Leu mutation. Venous blood was drawn for the determination of hemostatic variables and lipids. Factor XIII genotype was determined through a single-stranded conformational polymorphism technique and plasminogen activator inhibitor (PAI)-1 4G/5G promoter genotype by allele-specific polymerase chain reaction. Results —The mutation was more frequent in patients with primary intracerebral hemorrhage (n=62) (54.8%; P =.05) than in control subjects (41.7%) or in patients with cerebral infarction (n=529) (46.5%; P =.22). There was no relationship between PAI-1 levels and the PAI-1 4G/5G genotype. Conclusions —There was a slightly higher incidence of factor XIII Val 34 Leu in patients with PICH. This may be related to impaired cross-linking of fibrin and/or coagulation proteins.Keywords
This publication has 8 references indexed in Scilit:
- Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Promoter Polymorphism and Levels in Subjects with Cerebrovascular DiseaseThrombosis and Haemostasis, 1997
- Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levelsBlood, 1994
- Prospective study of endogenous tissue plasminogen activator and risk of strokeThe Lancet, 1994
- Fibrinogen and Viscosity as Risk Factors for Subsequent Cardiovascular Events in Stroke SurvivorsAnnals of Internal Medicine, 1992
- Classification and natural history of clinically identifiable subtypes of cerebral infarctionThe Lancet, 1991
- The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.JCI Insight, 1980
- Effects of calcium ion and covalent crosslinking on formation and elasticity of fibrin gelsThrombosis Research, 1975